Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.58 |
| ▸ | TTR | P02766 | 3/20 | 0.58 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.58 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.58 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.58 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.58 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.58 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.58 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.58 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.58 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31446274 | 0.82 | AKR1B1 (0.67) | CXCL8LMNAKMT2AAKR1B1FABP4 | |
| SCHEMBL4435429 | 0.82 | AKR1B1 (0.67) | CXCL8LMNAKMT2AAKR1B1FABP4 | |
| SCHEMBL7164963 | 0.80 | TTR (0.66) | PTGS2TTRCXCL8PTGS1ABCB11 | |
| SCHEMBL7160794 | 0.79 | PTGS2 (0.62) | PTGS2TTRCXCL8PTGS1ABCB11 | |
| Diclofenac SCHEMBL27702296 | 0.78 | PTGS2 (0.89) | PTGS2TTRCXCL8PTGS1ABCB11 | |
| SCHEMBL8683168 | 0.77 | CA12 (0.55) | LMNAMAPK1AKR1B1CYP3A4GAA | |
| Diclofenac SCHEMBL15416401 | 0.76 | PTGS2 (0.91) | PTGS2TTRCXCL8PTGS1ABCB11 | |
| SCHEMBL22140746 | 0.76 | MAPT (0.56) | CXCL8MAPK1KMT2ACLCN2FABP4 | |
| Diclofenac SCHEMBL7776173 | 0.75 | PTGS2 (0.89) | PTGS2TTRCXCL8PTGS1ABCB11 | |
| SCHEMBL3008967 | 0.75 | FABP4 (0.54) | PTGS2TTRCXCL8PTGS1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552077-B2 | Kidney disorders | EXOCELL, INC. | 2003-04-22 | — | — | US | disclosed |
| US-6355680-B1 | BLOCKING REACTION OF GLUCOSE AND ALBUMIN | EXOCELL, INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | EXOCELL, INC. | 2001-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | ALB, AGER, TTR | PTGS2 2067/4885TTR 3/4885CXCL8 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.